One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.

Autor:	Richez B; Department of Anesthesia-Intensive Care, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Cantarel C; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Durrieu F; Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Soubeyran I; Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Blanchi J; Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Pernot S; Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Chakiba Brugère C; Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Roubaud G; Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Cousin S; Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Etienne G; Hematology Department, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Floquet A; Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Babre F; Department of Anesthesia-Intensive Care, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Rivalan J; Department of Anesthesia-Intensive Care, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Lalet C; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Narbonne M; Department PRISME, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Belaroussi Y; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France., Bellera C; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France.; Epicene Team, UMR 1219, Bordeaux Population Health Research Center, University Bordeaux, Inserm, F-33000 Bordeaux, France., Mathoulin-Pélissier S; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France.; Epicene Team, UMR 1219, Bordeaux Population Health Research Center, University Bordeaux, Inserm, F-33000 Bordeaux, France.
Jazyk:	angličtina
Zdroj:	International journal of environmental research and public health [Int J Environ Res Public Health] 2023 May 25; Vol. 20 (11). Date of Electronic Publication: 2023 May 25.
DOI:	10.3390/ijerph20115949
Abstrakt:	Infection of SARS-CoV-2 among health workers (HWs) in contact with cancer patients has been a major issue since the beginning of the pandemic. We aimed to assess the serological immune status of SARS-CoV-2 infection among these HWs. A prospective cohort study was initiated in the comprehensive cancer center of the Nouvelle-Aquitaine region (NA, France). Volunteer HWs working on March 2020 without active infection or symptoms of COVID-19 completed a self-questionnaire and had a blood test at inclusion, at 3 and 12 months. Positive serological status of SARS-CoV-2 infection was defined by anti-nucleocapsid antibodies and/or IgG anti-spike antibodies, except at 12 months due to vaccine. Half of the HWs were included (N = 517) and 89% were followed for three months (N = 500) and one year (N = 462). Seroprevalence of SARS-CoV-2 infection was 3.5% (95% CI: 1.9-5.1), 6.2% (95% CI: 4.1-8.3), and 10% (95% CI: 7.2-12.7) on June-September 2020, September 2020-January 2021, and June-October 2021, respectively. At 12 months, 93.3% had detectable antibodies with 80% vaccinated in the first three months of vaccine availability. The COVID-19-free policy of the institution, respect for barrier gestures, high and early vaccination of HWs, and low prevalence of SARS-CoV-2 in NA may explain the low rate of seropositivity among the HWs of the Institut Bergonié.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu